Optimization of 3‑Cyano-7-cyclopropylamino-pyrazolo[1,5‑a]pyrimidines toward the Development of an In Vivo Chemical Probe for CSNK2A
Xuan Yang,
Han Wee Ong,
Rebekah J. Dickmander,
Jeffery L. Smith,
Jason W. Brown,
William Tao,
Edcon Chang,
Nathaniel J. Moorman,
Alison D. Axtman,
Timothy M. Willson
Affiliations
Xuan Yang
Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Han Wee Ong
Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Rebekah J. Dickmander
Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina, United States
Jeffery L. Smith
Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Jason W. Brown
Takeda Development Center Americas, Inc., San Diego, California, United States
William Tao
Takeda Development Center Americas, Inc., San Diego, California, United States
Edcon Chang
Takeda Development Center Americas, Inc., San Diego, California, United States
Nathaniel J. Moorman
Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina, United States
Alison D. Axtman
Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Timothy M. Willson
Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
